Blueprint Medicines Technical Analysis

Blueprint Medicines Corporation -- USA Stock  

USD 64.21  0.72  1.11%

Blueprint Medicines Corporation shows Downside Deviation of 2.24, Risk Adjusted Performance of 0.033 and Mean Deviation of 1.82. Blueprint Medicines technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm future prices. In plain English you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum or the prices will eventually revert. We found nineteen technical drivers for Blueprint Medicines Corporation which can be compared to its rivals. Please confirm Blueprint Medicines Treynor Ratio as well as the relationship between Potential Upside and Expected Short fall to decide if Blueprint Medicines is priced correctly providing market reflects its regular price of 64.21 per share. Given that Blueprint Medicines has Jensen Alpha of (0.27), we suggest you validate Blueprint Medicines Corporation prevailing market performance to make sure the company can sustain itself at future point.
Investment Horizon     30 Days    Login   to change

Blueprint Medicines Trend Analysis

Use this graph to draw trend lines for Blueprint Medicines Corporation. You can use it to identify possible trend reversals for Blueprint Medicines as well as other signals and approximate when it will take place. Remember, you need at least two touches of the trend line with actual Blueprint Medicines price movement. To start drawing, click on the pencil icon on top-right. To remove the trend, use eraser icon.

Blueprint Medicines Best Fit Change Line

The following chart estimates an ordinary least squares regression model for Blueprint Medicines Corporation applied against its price change over selected period. The best fit line has a slop of 0.34 % which may suggest that Blueprint Medicines Corporation market price will keep on failing further. It has 34 observation points and a regression sum of squares at 92.97, which is the sum of squared deviations for the predicted Blueprint Medicines price change compared to its average price change.

Did you try this?

Run Portfolio Rebalancing Now

Portfolio Rebalancing

Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Hide  View All  Next  Launch Portfolio Rebalancing
Blueprint Medicines Corporation is rated fifth in mean deviation category among related companies. It is currently under evaluation in standard deviation category among related companies creating about  1.23  of Standard Deviation per Mean Deviation. The ratio of Standard Deviation to Mean Deviation for Blueprint Medicines Corporation is roughly  1.23